Understanding how C5aR1 signaling affects kidney disease progression
Unanticipated roles of C5aR1 Signaling Leading from Acute to Chronic Kidney Disease
This study is looking at how a specific signaling pathway in the body might help us understand and prevent the worsening of kidney problems, especially for people who have had acute kidney injury, with the hope of finding new treatments to protect kidney health.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11093331 on NIH RePORTER |
What this research studies
This research investigates the role of C5aR1 signaling in the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). It aims to explore how this signaling pathway affects kidney cells and immune responses, potentially leading to new therapeutic strategies. By examining the effects of C5aR1 activation on kidney resident macrophages and renal tubular epithelial cells, the study seeks to uncover mechanisms that could prevent the progression of kidney damage. Patients may benefit from insights that could lead to innovative treatments for kidney diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have experienced acute kidney injury and are at risk for developing chronic kidney disease.
Not a fit: Patients with chronic kidney disease unrelated to acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent the progression of acute kidney injury to chronic kidney disease.
How similar studies have performed: Other research has shown promising results in targeting complement pathways for kidney protection, suggesting potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Yu, Mon-Wei — Icahn School of Medicine at Mount Sinai
- Study coordinator: Yu, Mon-Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.